Cargando…

Will Research on COVID-19 Stimulate the Identification of Immunological Mechanisms Underlying Some Protective Effects?

Detalles Bibliográficos
Autores principales:	Incorvaia, Cristoforo, Ridolo, Erminia, Febo, Oreste C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919161/ https://www.ncbi.nlm.nih.gov/pubmed/33064955 http://dx.doi.org/10.1513/AnnalsATS.202009-1139LE

Ejemplares similares

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
por: Pucciarini, Francesco, et al.
Publicado: (2022)

Can the Pattern of Early Sensitization to Allergen Molecules Drive a New Approach for Prevention of Allergy?
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence
por: Martignago, Irene, et al.
Publicado: (2017)

Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

The quest for improving general and in hospital health care during COVID-19 pandemic
por: Ridolo, Erminia, et al.
Publicado: (2021)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

About the effect of pulmonary rehabilitation on lung function in patients with chronic obstructive pulmonary disease
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults
por: Ridolo, Erminia, et al.
Publicado: (2019)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Two decades with omalizumab: what we still have to learn
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

What still prevents to acknowledge a major role for pulmonary rehabilitation in COPD treatment?
por: Incorvaia, Cristoforo, et al.
Publicado: (2019)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Local allergic rhinitis: evolution of concepts
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Personalized medicine and allergen immunotherapy: the beginning of a new era?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis
por: Ridolo, Erminia, et al.
Publicado: (2021)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Current treatment strategies for seasonal allergic rhinitis: where are we heading?
por: Ridolo, Erminia, et al.
Publicado: (2022)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Patient's Adherence and Compliance and Quality of Life During/After VIT
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Patient’s compliance with allergen immunotherapy
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

Omalizumab, an anti-immunoglobulin E antibody: state of the art
por: Incorvaia, Cristoforo, et al.
Publicado: (2014)

Maximizing rehabilitation outcomes in geriatric hip fracture patients: the impact of surgical variables
por: Amata, Oriana, et al.
Publicado: (2023)

Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
por: Incorvaia, Cristoforo, et al.
Publicado: (2023)

How to fit allergen immunotherapy in the elderly
por: Ridolo, Erminia, et al.
Publicado: (2017)

Lipid transfer protein syndrome: How to save a life through careful education
por: Ridolo, Erminia, et al.
Publicado: (2022)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
por: Frati, Franco, et al.
Publicado: (2014)

Importance of hypersensitivity in adverse reactions to drugs in the elderly
por: Ventura, Maria Teresa, et al.
Publicado: (2018)

Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study
por: Savi, Eleonora, et al.
Publicado: (2017)

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms
por: Ventura, Maria Teresa, et al.
Publicado: (2017)

Low incidence of pneumonia in COPD patients treated with inhaled corticosteroids undergoing pulmonary rehabilitation
por: Ridolo, Erminia, et al.
Publicado: (2018)

One more step towards a deeper understanding of the mechanisms of allergen immunotherapy
por: Incorvaia, Cristoforo
Publicado: (2018)

Could a bite trigger the onset of cat allergy?
por: Leo, Gualtiero, et al.
Publicado: (2022)

Indeterminate Form of Chagas Disease: Some Immunological Insights
por: Matos, Daniel Mazza, et al.
Publicado: (2022)

Some latest achievements in immunology research
por: Liu, Wei
Publicado: (2011)

Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
por: Boni, Elisa, et al.
Publicado: (2016)

Do not intubate order, is the misunderstanding finally over?
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9qn1ttb5ksjkv57crd7i0lskl2